Sponsored Links
| Survival In Refractory Lung Cancer Patients Extended By Drug Combination |
 |
 |
 |
| Medical News - Lung Cancer | |||
|
Scientists have identified a drug combination, when used in advanced lung cancer patients, shows a survival advantage in patients who no longer respond to existing therapies. They found that bexarotene and erlotinib can each repress the critical cell cycle regulator: cyclin D1... Read more: Lung Cancer News From Medical News Today
|